| 1.05 -0.1 (-8.7%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.47 | 1-year : | 3.31 |
| Resists | First : | 2.11 | Second : | 2.83 |
| Pivot price | 1.48 |
|||
| Supports | First : | 0.95 | Second : | 0.79 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.53 |
| MA(100) : | 1.06 |
MA(250) : | 1.06  |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 4.3 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 2.83 | Low : | 0.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CNTB ] has closed above bottom band by 21.9%. Bollinger Bands are 264.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 43 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.16 - 1.17 | 1.17 - 1.17 |
| Low: | 0.94 - 0.94 | 0.94 - 0.95 |
| Close: | 1.14 - 1.15 | 1.15 - 1.16 |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Tue, 28 Nov 2023
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical ... - Yahoo Finance
Tue, 21 Nov 2023
U.S. shares lower at close of trade; Dow Jones Industrial Average ... - Investing.com Canada
Tue, 21 Nov 2023
Pre-Market Most Active for Nov 21, 2023 : CSX, SBSW, ANGH ... - Nasdaq
Mon, 20 Nov 2023
Connect Biopharma to Announce Long-Term Data from the China ... - Yahoo Finance
Thu, 09 Nov 2023
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest ... - Yahoo Finance
Mon, 06 Nov 2023
Is Connect Biopharma Holdings (CNTB) Outperforming Other ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 39.8 (%) |
| Held by Institutions | 39.8 (%) |
| Shares Short | 29 (K) |
| Shares Short P.Month | 26 (K) |
| EPS | -1.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29 % |
| Return on Equity (ttm) | -51.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -553 (M) |
| Levered Free Cash Flow | -389 (M) |
| PE Ratio | -0.68 |
| PEG Ratio | 0 |
| Price to Book value | 0.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|